• DOI:10.1007/s40272-017-0242-4
Corpus ID: 24857218

AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity

@article{Syed2017AbobotulinumtoxinAAR,
  title={AbobotulinumtoxinA: A Review in Pediatric Lower Limb Spasticity},
  author={Yahiya Y. Syed},
  journal={Pediatric Drugs},
  year={2017},
  volume={19},
  pages={367-373}
}

Yahiya Y. Syed

Published 2017

Medicine

Pediatric Drugs

AbobotulinumtoxinA (Dysport®) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10–15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed